Immunotherapy in Small Cell Lung Cancer: Clinical Trial Updates and Emerging Strategies Across Limited and Extensive Stage Disease

Small cell lung cancer's stark divide between curable, localized disease and systemic, incurable disease shapes every treatment decision that follows, and screening gains are slowly shifting how many patients get caught early enough to benefit.

Concurrent chemoradiotherapy remains curative-intent therapy for limited-stage disease, yet cure rates without immunotherapy stall near thirty percent, a ceiling that scheduling choices and careful monitoring can only partly raise on their own.